- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05731076
Self-Management Support for Lung Cancer Patients With Cachexia
Efficacy of Self-Management Support on Nutritional Status in Lung Cancer Patients With Cancer Cachexia Syndrome: A Randomized Clinical Trail
The goal of this randomized clinical trial is to evaluate the efficacy of a self-management support program combining exercise and nutrition intervention for lung cancer patients with cancer cachexia anorexia syndrome.
This study is conducted in two stages. In the first stage (Pilot Phase), the researchers aim to assess the feasibility of the intervention and its potential impact on nutritional status in 20 participants. Based on these preliminary results, the intervention protocol or supervision model may be refined for the subsequent full-scale trial.
The main questions it aims to answer are:
Is the combined exercise and nutrition self-management support program feasible for lung cancer patients with cachexia?
Can this integrated intervention improve the nutritional status of these patients compared to routine care?
Participants in the intervention group will receive self-management support-based education to develop personalized exercise plans and ensure adequate protein intake. The researchers will compare this group to a control group receiving routine health education to evaluate differences in nutritional outcomes.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Changhua
-
Changhua, Changhua, Taiwan, 51052
- Changhua Christian Hospital
-
-
Taipei
-
Taipei, Taipei, Taiwan, 11219
- Taipei Veterans General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosed lung cancer(ICD-10 code: C33-C34)
- Body weight loss: body weight loss 2% before recruitment 2 months or body weight loss 5% before recruitment 6months.
- Physician judged may do home exercise without supervisor.
- Has smart phone and agree to use exercise associated application.
- Agree to wear Xioami smart band as long as passible.
- Conscious clear and communication.
- Eastern Cooperative Oncology Group (ECOG) 0-1.
Exclusion Criteria:
- Participants with cardiovascular disease can't exercise without supervisor.
- Diabetes Mellitus with blood sugar poor control.
- Chronic obstructive pulmonary disease with dyspnea on exertion.
- Platelets < 50000mm3 due to disease or treatment.
- Hemoglobin <10mg/dl.
- Recently stumble, severe pain, cognitive and behavior change.
- Suspect or diagnosed brain metastasis.
- Suspect or diagnosed bone metastasis.
- Receive Nasogastric tube feeding or parenteral nutrition.
- Physician judged can't do home exercise.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Combined Exercise and Nutrition Self-management Support Program
Participants receive a 12-week multimodal intervention.
This includes personalized exercise prescriptions (aerobic, resistance, and flexibility training) guided by wearable technology and structured nutritional counseling focused on adequate protein intake (e.g., 1.2 g/kg/day).
All activities are supported by a self-management behavioral framework to enhance adherence.
In addition, both arms receive baseline cancer care from hospital case managers to ensure ethical standards of care are met.
|
A structured 12-week multimodal support program.
(1) Exercise: Personalized home-based aerobic, resistance, and flexibility training (at least 3 times/week, 30 min/session) monitored via Xiaomi smart bands.
(2) Nutrition: Goal-oriented counseling focused on achieving a high-protein intake (e.g., 1.2-1.5 g/kg/day).
(3) Self-management: Continuous support using a self-monitoring manual, wearable device feedback, and a dedicated Line@ social media platform for real-time interaction with researchers, providing counseling and symptom management support to enhance patient adherence.
|
|
No Intervention: Routine health education group
Participants will receive standard of care provided by cancer case managers, including education on medication adherence, symptom/side-effect management, and nutritional supplement trials as needed.
To maintain study blinding, participants in this group will also wear Xiaomi smart bands and undergo the same assessment schedule (Baseline, Week 8, Week 12) without the additional self-management support program.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline Mini Nutrition Assessment(MNA)
Time Frame: baseline, Week 8, Week 12.
|
The MNA consists of 18 self-reported questions covering ingestion, weight loss, mobility, acute illness/stress, neuropsychological problems, BMI, living arrangements, polypharmacy, skin ulcers, meal frequency, food/fluid intake, and mode of feeding.
The maximal score is 30.
A score >23.5 means well-nourished, 17-23.5 means risk of malnutrition, and <17 means malnutrition.
Higher scores indicate better nutritional status.
|
baseline, Week 8, Week 12.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of the self-management support program
Time Frame: Week 12
|
Assessed by recruitment rate (percentage of eligible patients enrolled), retention rate (percentage of participants completing the 12-week study), and adherence to the wearable device and Line@ interaction.
|
Week 12
|
|
Change from balseline in Body Mass Index(BMI)
Time Frame: Baseline, Week 8, Week 12
|
BMI is calculated as weight in kilograms divided by the square of height in meters (kg/m^2), measured using Bioelectrical Impedance Analysis (BIA) with the InBodyDial H20 device.
Data are recorded and rounded to one decimal place.
|
Baseline, Week 8, Week 12
|
|
Change from baseline in skeletal muscle mass
Time Frame: Baseline, Week 8, Week 12
|
Measured using Bioelectrical Impedance Analysis (BIA) with the InBodyDial H20 device.
Data are recorded in percentage (%) and rounded to one decimal place.
|
Baseline, Week 8, Week 12
|
|
Change from basleline body fat mass at 12weeks
Time Frame: Baseline, Week 8, Week 12
|
The body fat mass will be detected by InBodyDial H20.
Data record with percentage and after the first decimal place.
|
Baseline, Week 8, Week 12
|
|
Change from Baseline in Upper Body Muscle Endurance (30-Second Arm Curl Test)
Time Frame: Baseline, Week 8, Week 12
|
Used to evaluate upper body muscle endurance.
The participant sits on a chair with back supported and performs as many bicep curls as possible in 30 seconds using a dumbbell (5 lbs for females; 8 lbs for males).
The total number of completed curls is recorded.
Higher scores (more repetitions) indicate better upper body muscle endurance.
|
Baseline, Week 8, Week 12
|
|
Change from Baseline in Lower Body Muscle Strength (30-Second Chair-Stand Test)
Time Frame: Baseline, Week 8, Week 12
|
Used to evaluate lower body muscle strength.
The participant sits in the middle of a chair with back straight and feet flat on the floor, then stands up completely and sits down repeatedly for 30 seconds.
The total number of completed stands is recorded.
Higher scores (more repetitions) indicate better lower body muscle strength.
|
Baseline, Week 8, Week 12
|
|
Change from Baseline in cardiopulmonary function (6-Minute Walk Test)
Time Frame: Baseline, Week 8, Week 12
|
Examine cardiopulmonary function in this study.
Let the participant sit and rest 10 minutes before test.
Check vital signs and oxygen situation for patient safety.
Position the participant at the starting line, and walking back and forth along the mark on the floor.
When the participant starts to walk, starts the times.
Don't walk nor talk with him/ her, and count the laps attentively.
Participant can walk longer distance means better cardiopulmonary function.
|
Baseline, Week 8, Week 12
|
|
Change from basline in quality of life (FACT-L)
Time Frame: Baseline, Week 12
|
The Functional Assessment of Cancer Therapy-Lung (FACT-L) is used to determine quality of life in lung cancer patients.
It contains 5 dimensions: physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and lung cancer subscale (9 items).
Items are rated on a 5-point Likert scale with total scores ranging from 0 to 144.
Higher scores indicate better quality of life."
|
Baseline, Week 12
|
|
Change from Baseline in Cancer anorexia-cachexia syndrome nutrition knowledge (CACSNKQ)
Time Frame: Baseline, Week 12
|
The CACSNKQ is designed to assess patients' knowledge regarding cancer anorexia-cachexia syndrome.
All items are multiple-choice with one correct answer.
The total score ranges from 0 to 21, with higher scores indicating better nutritional knowledge and self-management ability against the syndrome.
|
Baseline, Week 12
|
|
Change from baseline in dietary intake (24 hours dietary recall)
Time Frame: Baseline, Week 8, Week12
|
To assess participants' nutritional intake.
A 24-hour dietary recall interview is conducted to record all food and beverage consumption (including dish names, portion sizes, and preparation methods).
Data are converted into total calories (kcal) and macronutrients (protein, fat, and carbohydrates in grams) by a registered dietitian using nutritional analysis software.
|
Baseline, Week 8, Week12
|
|
Change from Baseline in amount of exercise
Time Frame: Baseline to Week 8, and Week 8 to Week 12
|
Measured using the Xiaomi Smart Band and a self-management support manual.
The Xiaomi Smart Band is worn daily by participants to record continuous physical activity data, including daily step count, exercise duration, walking distance, and heart rate.
Additionally, participants use the self-management support manual to log the specific duration and frequency of resistance training and stretching exercises.
|
Baseline to Week 8, and Week 8 to Week 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Li Chun Chang, Master, Changhua Christian Hospital
- Study Director: Tsae Jyy Wang, PhD, National Taipei University of Nursing and Health Sciences
Publications and helpful links
General Publications
- Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011 May;12(5):489-95. doi: 10.1016/S1470-2045(10)70218-7. Epub 2011 Feb 4.
- Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, Zucker DS, Matthews CE, Ligibel JA, Gerber LH, Morris GS, Patel AV, Hue TF, Perna FM, Schmitz KH. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390. doi: 10.1249/MSS.0000000000002116.
- Ozaki H, Nakagata T, Yoshihara T, Kitada T, Natsume T, Ishihara Y, Deng P, Kobayashi H, Machida S, Naito H. Effects of Progressive Walking and Stair-Climbing Training Program on Muscle Size and Strength of the Lower Body in Untrained Older Adults. J Sports Sci Med. 2019 Nov 19;18(4):722-728. eCollection 2019 Dec.
- Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Hutterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Muhlebach S, Oldervoll L, Ravasco P, Solheim TS, Strasser F, de van der Schueren M, Preiser JC, Bischoff SC. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr. 2021 May;40(5):2898-2913. doi: 10.1016/j.clnu.2021.02.005. Epub 2021 Mar 15.
- Peddle-McIntyre CJ, Singh F, Thomas R, Newton RU, Galvao DA, Cavalheri V. Exercise training for advanced lung cancer. Cochrane Database Syst Rev. 2019 Feb 11;2(2):CD012685. doi: 10.1002/14651858.CD012685.pub2.
- Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hutterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Muhlebach S, Muscaritoli M, Oldervoll L, Ravasco P, Solheim T, Strasser F, de van der Schueren M, Preiser JC. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1):11-48. doi: 10.1016/j.clnu.2016.07.015. Epub 2016 Aug 6.
- Schreiber M, Bucher T, Collins CE, Dohle S. The Multiple Food Test: Development and validation of a new tool to measure food choice and applied nutrition knowledge. Appetite. 2020 Jul 1;150:104647. doi: 10.1016/j.appet.2020.104647. Epub 2020 Feb 29.
- Anderson LJ, Albrecht ED, Garcia JM. Update on Management of Cancer-Related Cachexia. Curr Oncol Rep. 2017 Jan;19(1):3. doi: 10.1007/s11912-017-0562-0.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 220582
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Neoplasm Malignant
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Metastatic Malignant Neoplasm in the LungUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Advanced Malignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMalignant Neoplasm | Malignant Respiratory Tract Neoplasm | Malignant Thoracic NeoplasmUnited States, Cyprus
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRefractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Cutaneous Melanoma | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System Neoplasm | Recurrent Lip and Oral Cavity Carcinoma | Recurrent Malignant Endocrine... and other conditionsUnited States
-
Mayo ClinicRecruitingMalignant Abdominal Neoplasm | Malignant Pelvic Neoplasm | Childhood Malignant Solid Neoplasm | Childhood Malignant Thoracic Neoplasm | Malignant Neck Neoplasm | Metastatic Childhood Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid NeoplasmUnited States, Canada
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Rare Malignant Solid Neoplasm | Rare Malignant Solid Neoplasm | Refractory Rare Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterTerminatedLocally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Neoplasm | Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
Clinical Trials on Self-management support nutrition and exercise intervention
-
University of Colorado, DenverCompletedDiabetes Complications | Peripheral Arterial DiseaseUnited States
-
National Institute of Diabetes and Digestive and...Virginia Commonwealth University; Children's National Research InstituteCompleted
-
University of Southern DenmarkZealand University Hospital; Holbaek Sygehus; Naestved Hospital; Nykøbing Falster... and other collaboratorsCompletedDepression | Heart Failure | Hypertension | Chronic Obstructive Pulmonary Disease | Osteoarthritis, Knee | Coronary Heart Disease | Osteoarthritis, Hip | Type2 DiabetesDenmark
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ); San Francisco Health Plan...Completed
-
University of ArkansasPatient-Centered Outcomes Research InstituteCompletedDiabetes Mellitus, Type 2United States
-
Universitätsklinikum Hamburg-EppendorfGerman Federal Ministry of Education and ResearchCompletedMajor Depressive Disorder, Single Episode, Unspecified | Anxiety Depression (Mild or Not Persistent) | Neurotic, Stress-related and Somatoform DisordersGermany
-
The University of Hong KongRecruitingChronic Obstructive Pulmonary DiseaseHong Kong
-
Université de SherbrookeFonds de la Recherche en Santé du Québec; Agence de la Sante et des Services... and other collaboratorsCompletedChronic DiseasesCanada
-
Maastricht University Medical CenterAtrium Medical CenterUnknown
-
Johns Hopkins UniversityCompleted